
# A minimal PBPK model with a nested endosome compartment to predict the enhanced target suppression of recycling antibody vs. conventional antibody

Dongfen Yuan ACoP 2024 Phoenix, AZ

Yuan et al. AAPS J. 2018 Yuan et al. Eur J Pharm Sci. 2019






#### **Outline**


- The role of FcRn in antibody PK
- What and why of recycling antibody
- Modeling: extension of mPBPK model with a nested endosome compartment to describe the enhanced target suppression of recycling antibody vs. conventional antibody
- Shiny App demonstration

#### FcRn-mediated antibody recycling reduces antibody clearance




### Conventional antibody against soluble target reduces antigen clearance and can bind to the target only once

**Antibody-mediated** target accumulation




# Recycling antibody against soluble target can bind to the antigen multiple times




### **Modeling & Simulation objectives**


- Predict the benefit of recycling antibodies based on in vitro target binding affinity
- Facilitate the interspecies translation of recycling antibodies




# Minimal PBPK model serves as the base model to facilitate interspecies translation



Tight tissues: muscle, skin, adipose, brain Leaky tissues: liver, spleen, kidney, heart, etc. An endosome compartment was nested to simulate the difference between conventional and recycling antibodies




### Endosome trafficking and FcRn recycling pathway were incorporated to the base model




k1<sub>on</sub>/k1<sub>off</sub>: antibody-FcRn association/dissociation rate constants

### Non-specific pinocytosis rate and lysosomal catabolism rate were estimated from human data

- FcRn functional human
- FcRn mutant human (familial hypercatabolic hypoproteinemia)






### The model can predict the PK of mAbs with different FcRn binding affinities in human


#### Adalimumab (672 nM)

Dose (mg/kg) • 0.25 ▲ 0.5 ■ 1 + 3 ⊠




#### Infliximab (727 nM)






# A complementary mouse model can predict the extended circulation of Fc-engineered antibody in mice


#### Estimation of CL<sub>up</sub> and CL<sub>e</sub> in mice





(non-specific pinocytosis rate)

### Target binding kinetics in plasma and endosomes were added to describe the difference between recycling and conventional antibodies




A: antibody

T: soluble target

ATC: antibody-target complex


### Model predicts reduced antigen accumulation for a recycling antibody in mice



# Increasing target dissociation rate constant at pH 6 can efficiently enhance target suppression


10x stepwise decrease of  $K_{eon}$  at pH 6

10x stepwise increase of K<sub>eoff</sub> at pH 6




Solid lines: antibody Dashed lines: target


### Most targets were bound to antibodies in endosomes, thus increasing target dissociation rate constant is more efficient in releasing the targets



## The model was scaled to monkey and rabbit to facilitate interspecies translation




## Interspecies scaling of non-specific pinocytosis $CL_{up}$ using exponent of 0.83



Yuan et al. Eur J Pharm Sci. 2019

# A generic model for recycling antibodies against soluble target in human, mouse, monkey, and rabbit





A: antibody


T: soluble target

ATC: antibody-target complex


# Recycling antibody can prolong the suppression of soluble target by reducing membrane target-mediated antibody clearance







### **Shiny App Demonstration**



A: antibody

T: soluble target

ATC: antibody-target complex